Evidence map›Paper›PMID 39301117›Full record

ArticleUrology case reports2024

Utility of pembrolizumab for metastatic castrate resistant prostate cancer with MMR deficiency.

Brian F Dinerman, Andrew Skomra, Iryna Dovirak, John Rutkowski

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Brian F DinermanUniversity at Buffalo Jacobs School of Medicine and Biomedical Sciences, Department of Urology, Buffalo, NY, USA.
Andrew SkomraUniversity at Buffalo Jacobs School of Medicine and Biomedical Sciences, Department of Urology, Buffalo, NY, USA.
Iryna DovirakUniversity at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA.
John RutkowskiUniversity at Buffalo Jacobs School of Medicine and Biomedical Sciences, Department of Urology, Buffalo, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Molecular tumor profiling has become an important diagnostic for prostate cancer, allowing for personalized treatment regimens based on somatic and germline genetic information. We report a 67-year-old patient with metastatic castrate-resistant prostate cancer which was intermittently responsive to androgen-deprivation therapy, docetaxel, abiraterone, radium-223, Sipuleucel-T, and radiotherapy who ultimately demonstrated a remarkable and durable response to pembrolizumab. Our case report underlines the significance of early tumor molecular profiling in aggressive or atypical prostate cancer patients and exhibits the potential for a remarkable clinical response with immunotherapy in candidates with the appropriate tumor profiles.

Indexed as

Germline testingMetastatic castrate-resistant prostate cancerMismatch repair deficiencyPembrolizumab

Identifiers

PMID39301117
PMCPMC11408038

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.